在全身性硬化症中治疗间歇性肺病:指南和新的临床试验结果
Sindhu R Johnson1, Elana J Bernstein2
1Toronto Scleroderma Program, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Current opinion in rheumatology
|August 28, 2024
概括
系统性硬化症相关的间歇性肺病 (SSc-ILD) 治疗指南是由最近的随机试验提供信息. 证据支持用于SSc-ILD管理的免疫抑制和抗纤维素药物.
科学领域:
- 风湿病学和肺部病学
- 临床药理学 临床药理学
- 基于证据的医学基于证据的医学.
背景情况:
- 系统性硬化症相关的间歇性肺病 (SSc-ILD) 是死亡的主要原因.
- 美国风湿病学学院 (ACR) 和美国胸部医师学院 (CHEST) 最近的临床实践指南涉及SSc-ILD治疗.
- 药理疗法是管理SSc-ILD的核心.
研究的目的:
- 对SSc-ILD的药理疗法进行随机试验的证据进行审查.
- 评估这些治疗方法的安全性和有效性.
- 为SSc-ILD.提供ACR/CHEST指南的信息.
主要方法:
- 在SSc-ILD.中对随机对照试验 (RCT) 的系统审查.
- 对免疫抑制药物的数据分析.
- 对抗纤维菌药物的数据分析.
主要成果:
- 评估的免疫抑制药物包括mycophenolate,cyclophosphamide,rituximab和tocilizumab. 这些药物被认为是免疫抑制药物.
- 评估的抗纤维素药物包括宁泰达尼布和皮尔芬尼.
- 随机试验结果为当前的治疗建议提供了证据基础.
结论:
- 随机试验支持ACR/CHEST对SSc-ILD治疗的指导方针.
- 这些指导方针帮助临床实践管理SSc-ILD.
- 需要进一步的研究来完善SSc-ILD的治疗策略.
相关概念视频
COPD: Pathogenesis and Clinical Features
246
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
246
Drugs Used in Lower Respiratory Disorders: Overview
367
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
367
Cystic Fibrosis: Management
148
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
148
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
COPD: Management Using Bronchodilators and Corticosteroids
190
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
190
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162


